Evidence map›Paper›PMID 35266189›Full record

Trial reportNeurourology and urodynamics2022

App-based self-management of urgency and mixed urinary incontinence in women: One-year follow-up.

Towe Wadensten, Emma Nyström, Anneli Nord, Anna Lindam, Malin Sjöström, Eva Samuelsson

3 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neurourology and urodynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06797245 narecruitingnot on this mapstarted 2025, after this paper: background citation

The APPROVE Trial: A Randomized Controlled Trial Evaluating the Efficacy and Safety of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women

TypeinterventionalSponsorMedstar Health Research InstituteRan2025 to 2028Enrolled596ConditionsOveractive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), NocturiaArmsRiSolve App, AUGS Patient Handouts
NCT07038811 recruitingnot on this mapstarted 2025, after this paper: background citation

Implementation of the App Tät®II for Treatment of Urgency and Mixed Urinary Incontinence

TypeobservationalSponsorUmeå UniversityRan2025 to 2027Enrolled60ConditionsUrgency Incontinence, Mixed Incontinence, Urge and StressArmsTät®II
NCT07206446 nacompletednot on this mapstarted 2025, after this paper: background citation

A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

TypeinterventionalSponsorUniversity of GalwayRan2025 to 2026Enrolled46ConditionsOveractive Bladder (OAB), Over Active BladderArmsRiSolve
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Towe WadenstenFamily Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0002-4874-221X
Emma NyströmFamily Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0003-1745-6808
Anneli NordFamily Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0001-9804-3292
Anna LindamFamily Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Malin SjöströmFamily Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0003-0868-6249
Eva SamuelssonFamily Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0002-8549-0007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the long-term effect of the Tät®II app for treatment of urgency (UUI) and mixed urinary incontinence (MUI).

methodsLong-term follow-up of a randomized controlled trial, including 123 women ≥18 years old with UUI or MUI, without red-flag symptoms, and ≥2 leakages per week. All participants, regardless of group, had received the intervention, a treatment app, at the long-term follow-up. Long-term data were collected through web-based questionnaires 15 months after participants received the intervention. The app included pelvic floor muscle training, bladder training, psychoeducation, lifestyle advice, an exercise log, reminders, reinforcement messages, and tailored advice. The primary outcome was a change in incontinence symptoms (International Consultation on Incontinence Questionnaire [ICIQ]-Urinary Incontinence Short Form [ICIQ-UI SF]), from baseline to follow-up. Other outcomes were urgency symptoms (ICIQ-Overactive Bladder Module (ICIQ-OAB)), quality of life (ICIQ-Lower Urinary Tract Symptoms Quality of Life Module [ICIQ-LUTSqol]), and improvement (Patient's Global Impression of Improvement [PGI-I]).

resultsOf the 123 women, 102 (83%) completed the long-term follow-up. The ICIQ-UI SF mean score improved from 11.5 to 7.6 (mean difference 4.0, 95% CI 3.2-4.7). The ICIQ-OAB improved from 6.7 to 5.5 (mean difference 1.3, 95% CI 0.9-1.6) and the ICIQ-LUTSqol improved from 38.0 to 30.9 (mean difference 7.1, 95% CI 5.7-8.5). Of the 102 women, 74 (73%) reported improvement.

conclusionsSelf-management with the Tät®II app for UUI and MUI had a significant effect across all outcome measures also long-term and might serve as an alternative first-line treatment for these conditions.

Indexed as

Mobile ApplicationsSelf-ManagementUrinary IncontinenceUrinary Incontinence, StressAdolescentFemaleFollow-Up StudiesHumansQuality of LifeSurveys and QuestionnairesTreatment OutcomeUrinary Incontinence, UrgeeHealthlong-term follow-upmHealthmixed urinary incontinencemobile apptelehealthtreatmenturgency urinary incontinence

Identifiers

PMID35266189
PMCPMC9313824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.